Novartis Korea to resubmit world data for Sebivo.

Published: 2007-07-18 06:58:00

Updated: 2007-07-18 06:58:00

Novartis Korea was embarrassed at encountering the NHI price approval rejection for Sebivo (telbivudine), a chronic B hepatitis therapy on July 12, and CEO Andrin Oswald of Novartis Korea regretted to say "No chances for us to hear from the government why the product price was high nor to presen...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK